🦷 Toregem Biopharma & USAG‑1 — Explained

What is USAG‑1?

USAG‑1 (Uterine Sensitization‑Associated Gene‑1) is a protein that suppresses natural tooth growth by inhibiting the signaling pathways that allow tooth buds to develop.
[biztechspark.com], [dentistryunited.com]

In most people, the third set of tooth buds (after baby and adult teeth) becomes dormant and degenerates. USAG‑1 is one of the biological regulators responsible for shutting this process down.

---

🧪 Toregem’s Approach: Blocking USAG‑1

Monoclonal Antibody Against USAG‑1

Toregem Biopharma has developed a monoclonal antibody drug, officially named TRG035, which neutralizes USAG‑1.
[biztechspark.com], [dentistryunited.com]

By inhibiting USAG‑1, the drug:

• Reactivates suppressed tooth buds
• Allows the development of a new, third set of natural teeth
• Uses the patient’s own regenerative biology

This is not a prosthetic solution like dentures or implants. It is true biological regeneration.

---

🐁 Scientific Evidence (Preclinical)

Animal studies (mice and ferrets) showed that blocking USAG‑1 with Toregem’s antibody:

• Successfully grew new, functional teeth
• Had minimal side effects
  [dentistryunited.com]

These results (published 2021, Science Advances) enabled the jump to human trials.

---

👨‍⚕️ Human Clinical Trials

First-in-Human Trial

• Launched: September–October 2024
• Sites: Kyoto University Hospital & Kitano Hospital
• Participants: 30 adult males (age 30–64) missing at least one molar
• Administration: Intravenous dosing over 11 months
  [dentistryunited.com]

Next Planned Trial

• Targeting children ages 2–7 with congenital anodontia
• This condition affects ~1% of the population
  [dentistryunited.com]

---

🏅 Regulatory and Development Milestones

Orphan Drug Status

• Sept 29, 2025: TRG035 designated as an Orphan Drug in Japan for severe congenital oligodontia.
  [toregem.co.jp]

FDA Engagement

• Nov 27, 2025: Toregem announced receipt of the FDA’s Pre‑IND meeting response—meaning U.S. trials are being prepared.
  [toregem.co.jp]

---

🧬 Why USAG‑1 Is a Breakthrough Target

Neutralizing USAG‑1 is powerful because it enables:

✔ Reactivation of dormant tooth buds

✔ Regrowth of natural, living teeth

✔ A biological alternative to implants and dentures

✔ A treatment for congenital conditions where teeth never form

Toregem’s research is the first in the world to push this concept into human clinical practice.
[biztechspark.com], [dentistryunited.com]

---

🚀 Summary